BVF Partners and Boulder Ventures led a $16m Series A round in Ambrosia Biosciences.

BVF Partners, an investment firm, and Boulder Ventures, a venture capital firm, led a $16m Series A round in Ambrosia Biosciences, a privately held drug discovery company. "Array BioPharma was among the best small molecule drug discovery teams on the planet. With the recent shut down of the Pfizer/Array R&D facility here in Boulder, we have re-assembled the Array medicinal chemistry team at Ambrosia to apply that same expertise to obesity," Kyle Lefkoff, Boulder Ventures Founding Partner and Ambrosia Executive Chairman.